Another nucleic acid testing agency was investigated for violating the law.
At noon on May 27, the official Weibo account of the Beijing Municipal Public Security Bureau announced that in response to the suspected illegal and criminal behavior of "Beijing Jinzhun Medical Testing Laboratory Co., Ltd." during the nucleic acid testing process, the Beijing police have filed a case against the company for investigation. , Wang Moumou (male, 43 years old), the legal representative of the laboratory, and others have been seized, and the case is under further work.
According to the company's investigation: Beijing Jinzhun Medical Laboratory Co., Ltd. was established on May 28, 2019, with a registered capital of 10 million yuan, and the legal representative is Wang Xuegang.
The major shareholder behind Beijing Jinzhun Medical Laboratory is Harbin Precision Gene Technology Co., Ltd., which holds 100% of the shares.
Among them, Wang Xuegang also holds a 34.1358% stake in Harbin Precision Gene Technology Co., Ltd., and is also the largest single shareholder of the latter.
The company's data also shows that Harbin Precision Gene Technology Co., Ltd. is a high-tech biological gene enterprise introduced into Heilongjiang Province by the Science and Technology Department of Heilongjiang Province and Harbin Venture Capital Group. The enterprise aims to establish an internationally leading genome research and application in Harbin center.
At present, the Beijing Municipal Public Security Bureau has not notified Beijing Jinzhun Medical Laboratory Co., Ltd. of any illegal contents during the nucleic acid detection process.
However, the company received an administrative penalty from the Haidian District Health and Health Commission of Beijing in January this year. According to Jinghaiwei Medical Punishment [2022] No. 0037, according to Article 48 of the "Regulations on the Administration of Medical Institutions", "Medical Institutions" According to Article 81 of the Detailed Rules for the Implementation of the Administrative Regulations, the company "appoints non-health technicians to engage in medical and health technical work (medical institutions that use health technicians to engage in diagnosis and treatment activities other than their own specialties shall be treated as using non-health technicians)" Subject to administrative punishment, a fine of 1,000 yuan.
This is also the second time that Beijing has recently discovered that a nucleic acid testing agency is suspected of violating the regulations.
On May 20, the Beijing Fangshan District government website announced that Beijing Pu Shi Medical Laboratory Co., Ltd. was revoked by the Beijing Fangshan District Health Commission's "Medical Institution Practicing License".
The administrative punishment information shows that on May 14, 2022, the supervisor found that the original test data of Beijing Pushi Medical Laboratory Co., Ltd. located at 315-323, 3rd floor, Building 1, No. 9, Guangyang Street, Fangshan District, Beijing, was significantly less than the sample test. quantity.
At that time, the market also speculated that behind the investigation of Pu Shi Medical, there may be a situation in which a large batch of results were issued directly without testing.
Nucleic acid testing is one of the key measures for the prevention and control of the new crown epidemic.
To curb the rapid spread of the Omicron epidemic, the key lies in the early detection speed of nucleic acid testing. Therefore, higher requirements have been placed on the testing speed of nucleic acid testing companies.
At the press conference on the prevention and control of the new coronary pneumonia epidemic in Beijing held on the afternoon of May 9, Li Angzeng, deputy head of the quarantine and inspection working group of the leading group for the prevention and control of the new coronary pneumonia epidemic in Beijing, deputy director of the Beijing Municipal Health Commission and spokesperson The report stated that in the recent flight supervision and inspection, it was found that individual nucleic acid testing institutions had problems such as untimely submission of inspections, inaccurate reports, and lax laboratory management, which seriously affected the quality of nucleic acid testing and the effect of epidemic prevention and control.
Recently, a person from a nucleic acid enterprise told Yicai.com that the current frequent incidents of nucleic acid testing quality disturbances are likely to cause people's doubts about third-party testing institutions, which has caused certain problems to the development of the third-party laboratory industry. At the same time, in fact, It is not conducive to the prevention and control of the entire epidemic.
"Regardless of the current large-scale nucleic acid screening or normalized testing in the future, we must rely on and rely on third-party testing agencies." The nucleic acid testing industry source said that at present, he should call on the government to strengthen strict management of the entire chain of the nucleic acid testing industry. First of all Institutions applying to engage in the nucleic acid testing industry must fulfill the obligation of qualification review; in addition, strengthen the supervision of the entire nucleic acid service supervision process, and find problematic institutions, they must notify the outside world in detail through professional departments. On the one hand, it can act as a deterrent. , let other institutions learn from experience and lessons, and at the same time eliminate the blind rejection of third-party laboratory nucleic acid testing by the public; finally, once a truly non-compliant institution is found, its qualifications will be immediately revoked, and it must be punished according to laws and regulations.